Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma

NCT00640471 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00640471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00640471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2008
Completion date
January 10, 2013
Enrollment
750 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer